The mammalian Hippo signaling pathway has been implicated in the self-renewal and differentiation of stem and progenitor cells. MST1 and MST2 (MST1/2) are core serine-threonine kinases in the Hippo signaling pathway, one of which, MST1, has been extensively investigated for its role in T cell and myeloid cell function. These studies have identified MST1 as a promising therapeutic target in immunological disease. However, the roles of MST1/2 in hematopoietic stem cell (HSC) function in vivo are not fully understood. Here, we report that mice with a conditional deletion of Mst1/2 exhibit impaired hematopoietic stem and progenitor cell (HSPC) function under stress condition. Furthermore, Mst1/2 deletion markedly altered mature cell output. Therefore, MST1/2 are indispensable for maintenance as well as function of stem and progenitor cells under steady state conditions and with transplantation stress.
Flow cytometric analysis. Flow cytometry was performed as described previously 24 . BM cells were collected from femurs and tibias by flushing with fluorescence-activated cell sorting (FACS) buffer, consisting of phosphate-buffered saline (PBS) containing 2% fetal bovine serum (FBS) and 0.1% sodium azide. Splenocytes were obtained by mincing spleens on a 40-μm cell strainer with FACS buffer. Peripheral blood cells were collected from the tail vein or heart. White blood cell preparations were obtained after lysing red blood cells with an ammonium-chloride-potassium (ACK) lysis buffer. White blood cells were detected with biotin-conjugated antibodies against CD4 (RM4-5), CD8a (53-6.7), GR1 (RB6-8C5), CD11b (3A33), B220 (RA3-6B2), Nk1.1 (PK136) and TER119; LSKs (Lin − Sca1 + cKit + cells) were detected using Sca1-PE-Cy7 (D7) and cKit-APC (2B8) antibodies.
BrdU incorporation assay. Cells were obtained from mice 4 hours after injecting with BrdU (100 mg/kg, i.p.). Cells were then fixed, permeabilized and immunostained for cell surface markers (as detailed above) and BrdU using a BrdU FITC kit (BD Biosciences) as per the manufacturer's instructions. Short-term engraftment assay. Short-term engraftment assays were performed by transplanting 3 × 10 7 BM cells from Mst1/2-deficient or control (CD45.2 + ) mice into CD45.1 + mice. Three weeks after transplantation, donor cell chimerism was examined in BM, spleen, and thymus.
Homing assay. Homing assays were performed by transplanting carboxyfluorescein succinimidyl ester (CFSE)-labeled BM cells (4 × 10 6 ) from Mst1/2-deficient or control mice into lethally irradiated recipient mice. Sixteen hours after transplantation, CFSE + cells were assessed in BM, spleen, and peripheral blood (PB).
Colony Formation Assays.
For assessing hematopoietic progenitor cell activity, BM, spleen, and PB cells were counted and plated in methylcellulose medium (M3434, STEMCELL Technologies) 24 . The colony number is counted 7 days after plating.
Statistics. Sample sizes required for experiments were estimated based on preliminary results. No blinding or randomization was performed for any of the experiments. The statistical significance of differences between population means was assessed by two-tailed unpaired Student's t-test, unless otherwise indicated. Statistically significant differences (*p ≤ 0.05, **p ≤ 0.01) for pairwise comparisons between the indicated data points are shown. Statistical comparisons between individual data points and groups were not performed. The Kaplan-Meier log-rank test was used to analyze mouse survival data.
Results

Effects of Mst1/2 conditional deletion on mature cell subsets under homeostatic conditions.
To investigate the role of MST1 and MST2 in HSPCs, we crossed Mst1 floxed/floxed ;Mst2 −/− mice with Mx1-Cre transgenic mice 21, 22 in which Cre recombinase is activated by administration of pIpC 24 . Consistent with previous studies on lymphopenia 14 , B cells were dramatically decreased in the BM, spleen and peripheral blood (PB) from Mst1 floxed/floxed ;Mst2 −/− ;Mx1-Cre mice (referred to as DKO; Fig. 1A ). However, mild T cell lymphopenia was detected (data not shown). We also found that DKO mice showed erythropenia in the BM and myeloid expansion in BM, spleen, and PB (Fig. 1A) .
The absolute numbers of Lin − Sca1 + cKit + cells (LSKs), HSCs (Lin − Sca1 + cKit + CD150 + CD48 − ), and cycling HSCs (Lin − Sca1 + cKit + CD150 + CD48 + ) among BM cells from DKO mice were greater than those from control mice ( Fig. 1B and Fig. S2 ). In addition, lymphoid-primed multipotent progenitors (LMPPs; Lin − Sca1 + cKit + CD34 + FLT3 + ), common lymphoid progenitors (CLPs; Lin − Sca1 low cKit low CD127 + ), common myeloid progenitors (CMPs; Lin − Sca1 − cKit + CD34 + CD16/32 − ) and granulocyte-macrophage progenitors (GMPs; Lin − Sca1 − cKit + CD34 + CD16/32 + ) among BM cells from DKO mice were also increased in number, exhibiting increases comparable to or slightly less than those of HSCs ( Fig. 1B) . Mst1/2 deletion also led to a decrease in megakaryocyte-erythroid progenitors (MEPs; Lin − Sca1 − cKit + CD34 − CD16/32 − ) in the BM and a concomitant decrease in the number of erythroid cells in the BM (Fig. 1A,B ). Finally, Mst1/2-deficient progenitors could grow ex vivo into colonies than that of control (Fig. 1C ).
This HSC expansion phenotype also manifested in conventional Mst1-knockout mice. Notably, the absolute numbers of each HSC compartment in Mst1-deficient mice were also increased owing to a similar or slightly The expansion of HSC-enriched populations in Mst1/2-DKO mice is caused by increased proliferation and decreased apoptosis. To determine the cause of increased HSCs, we performed BrdU-incorporation assays in vivo. The proliferative activity of the HSC compartments, LSK and LSKFLT3 -, were both increased in Mst1/2-DKO mice ( Fig. 2A,B ). It has been reported that MST1/2 kinases are crucial in mediating/promoting apoptosis under conditions that stimulate apoptosis 17 . Therefore, we analyzed whether altered apoptosis could contribute to the expansion of HSCs in Mst1/2-DKO mice. We found that there were fewer apoptotic (annexin V + /DAPI − ) cells in HSC compartments from the Mst1/2-DKO mouse (Fig. 2C,D) . These data indicate that MST1/2 maintain HSC pools in vivo through regulation of proliferation and apoptosis.
HSCs were not exhausted in 6-month-old Mst1/2-DKO mice. Increased proliferation of HSCs leads to stem cell exhaustion, as exemplified by conditional Pten-deficient mice, which show stem cell depletion within 6 weeks after induction of Pten knockout (pIpC injection) 25 . To determine whether stem cells are depleted in Mst1/2-deficient mice, we analyzed the frequency of cells in HSC compartments 6 months after induction of Mst1/2 deletion by injection of pIpC ( Fig. 3A and B) . The frequencies of LSKs, HSCs and cycling HSCs were increased to levels similar to those in 3-week-old DKO mice, indicating that Mst1/2 DKO does not cause stem cell exhaustion. These data suggest that expansion of HSC numbers continued after Mst1/2 deletion and that the pools of these cells were maintained. Further, B cells were dramatically decreased in the BM, spleen and peripheral blood (PB) from in 6-month-old DKO mice as described before 26 (Fig. 3C ). We also found that DKO mice showed erythropenia in the BM and myeloid expansion in BM, spleen, and PB from in 6-month-old DKO mice. Collectively, we speculate that the reason why MST1/2 may expand HSC without exhaustion might be because MST1 and 2 modulate several functionally important targets in the other pathways that regulate an HSC program.
MST1/2 are required for HSC function under conditions of stress. To further test the function of
Mst1/2-deficient HSCs, we transplanted BM cells from pIpC injected control or Mst1/2-DKO (CD45.2 cells) mice together with competitor cells into lethally irradiated CD45.1 mice. Competitors provided normal mature blood cells after reconstitution. Three weeks after transplantation, mice transplanted with Mst1/2-deficient cells displayed significantly diminished repopulation of mature blood cells compared with WT controls (Fig. 4A ). This was caused by a decrease in HSCs and progenitor compartments of Mst1/2-deficient cells in transplanted (Fig. 4B ). To examine donor chimerism of test cells following transplantation, we monitored repopulation maintenance in mice for 4 months. All cell lineages were detected throughout this period after transplantation, although the populations were lower than those in controls ( Fig. 4C) and Mst1/2-deficient HSPCs were less well maintained at 4 months (Fig. 4D) .
To determine whether Mst1/2-deficient HSCs are capable of surviving under secondary stress conditions, we performed a second transplantation of primary transplanted control and Mst1/2-deficient cells. We found that each hematopoietic cell lineage was less effectively reconstituted by Mst1/2-deficient HSCs. As was the case for primary transplantation, the reconstitution efficiency of secondarily transplanted Mst1/2-deficient cells was lower than that of control cells (Fig. 4E) . These results indicate that MST1 and MST2 regulate BM engraftment efficiency.
The reduced homing activity of Mst1/2-deficient cells results in defective engraftment.
Engraftment efficiency can be determined by homing ability and/or proliferation/differentiation. Based on the increased HSC proliferation in Mst1/2-deficient mice, we suspected a defect in homing ability or engraftment efficiency of Mst1/2-deficient cells. To test short-term engraftment, we transplanted control or Mst1/2-deficient BM cells into non-irradiated CD45.1 recipient mice and examined donor cell chimerism in BM, spleen and thymus 3 weeks post-transplantation. Mst1/2-deleted HSPCs showed a decreased frequency of donor cell chimerism compared with controls ( Fig. 5A,B) . We further assessed the homing ability of Mst1/2-deficient BM cells by transplanting CFSE-labeled control or Mst1/2-deficient BM cells into lethally irradiated CD45.1 recipient mice (Fig. 5C ). Collectively, these data suggest that the regulation of HSC engraftment by MST1 and MST2 is due, at least in part, to effects on the homing step.
Discussion
In this study, we demonstrated that an Mst1/2 deficiency leads to defects in the hematopoietic system. First, we found that Mst1/2 deletion markedly altered mature cell output. Conditional Mst1/2-deficient mice exhibited severe B cell lymphopenia, and an increase in the myeloid cell population and mild erythropenia in BM, spleen, and PB. Second, we found that the loss of Mst1/2 caused an increase in the steady state HSC population, a phenotype attributable to increased proliferation and reduced apoptosis of HSCs. However, stem cell exhaustion was not observed in 6-month-old Mst1/2-DKO mice, indicating that Mst1/2-deficient HSCs had expanded and were capable of maintaining their pools in the BM. Third, Mst1/2 knockout in HSCs did not induce hyperplasia or spontaneous hematopoietic neoplasms up to the time of death (D.H. Lee, D. Lee and D.S. Lim, unpublished data).
We further found that the function of Mst1/2-deficient HSCs was impaired under stress conditions. Mst1/2-deficient recipient mice exhibited fewer mature cells in PB and significantly decreased HSC chimerism in BM compared with controls. Interestingly, Mst1/2-deleted BM cells showed a decreased frequency of donor cell SCIeNTIfIC RepoRTS | (2018) 8:942 | DOI:10.1038/s41598-018-19637-y chimerism and differences in their short-term engraftment (3 weeks) and homing (16 hours) ability compared with controls under acute transplantation stress conditions. These data suggest that the inefficient engraftment of Mst1/2-deficient BM cells in the acute stress transplantation setting is attributable to decreased homing ability. Collectively, our findings suggest that Mst1 and Mst2 regulate HSC function in a setting of acute stress.
Numerous studies have reported that MST1 and MST2 are important in T cell migration 18, 27, 28 . By extension, it is reasonable to suggest that MST1 and MST2 are also essential for HSC migration into BM and adhesion to the BM microenvironment. Consistent with this, Mst1/2-deficient HSCs accumulated abnormally in PB and spleen, a phenomenon caused by defective HSC retention in the BM niche. Accordingly, we suggest that MST1 and MST2 will prove to be key factors for improving future human HSC transplantation therapies using cord blood or adult blood. In summary, MST1 and MST2 control the production of mature hematopoietic cells and play an indispensable role in the maintenance and function of hematopoietic stem and progenitor cells.
